Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Background IL-23 expression is increased in psoriatic lesions and might regulate TH 17 T-cell counts in patients with psoriasis. Objectives We sought to test a novel IL-23–specific therapeutic agent for the treatment of psoriasis. Methods In this randomized, double-blind, placebo-controlled study th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2014-04, Vol.133 (4), p.1032-1040
Hauptverfasser: Sofen, Howard, MD, Smith, Stacy, MD, Matheson, Robert T., MD, Leonardi, Craig L., MD, Calderon, Cesar, PhD, Brodmerkel, Carrie, PhD, Li, Katherine, MS, Campbell, Kim, PhD, Marciniak, Stanley J., MBA, Wasfi, Yasmine, MD, PhD, Wang, Yuhua, PhD, Szapary, Philippe, MD, Krueger, James G., MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!